Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
WuXi AppTec, Inc. Drug Discovery Drug Development Biopharmaceuticals DELEGATE(S) Gonghua Pan 288 Fute Zhong Road, Waigaoqiao Free Trade Zone 200131 Shanghai China www.wuxiapptec.com Incorporated: 2000 Employees: 5000 Ownership: Public New York Stock Exchange: WX HIGHLIGHTS Recent Upcoming 02/23/2010: WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai. Shanghai, August 23,2011: PRNewswireAsia — WuXi AppTec Bioanalytical Services (BAS) unit had received a certificate of Good Laboratory 12/22/2009: WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year Practice (GLP) from the Organization for Economic Cooperation and Development (OECD) and EU. In 2009, WuXi received many outstanding service awards from its biotech and pharma partners such as Schering-Plough, Eli Lilly, BASF, Astrazeneca. 06/16/2011: WuXi AppTec Named a Top Ten Chinese Outsourcing Enterprise — Dr. Ge Li, Chairman and CEO, Named a Top Ten Contributor to China's Outsourcing Industry. MISSION/BACKGROUND WuXi AppTec is a leading global pharmaceutical, biologics, and medical device outsourcing company with operations in China and the US. We provide laboratory and manufacturing services from discovery to commercialization – helping shorten time to market and lower the cost of R&D. Our GMP and GLP facilities in China and the US (>2 million sq. ft.) are recognized by worldwide regulatory authorities (FDA, EMA, TGA, sFDA, KFDA, JMHLW and OECD). WuXi AppTec is listed (WX) on the NYSE with a market cap of >$1 billion USD. Biopharmaceutical Testing: GLP/GMP-compliant testing services for biologics. include cell line characterization, viral clearance validation, lot release, & stability studies. Pharmaceutical Discovery & Development: Fully integrated discovery and development programs including chemistry, biology, ADME, DMPK, pharmacology & safety. More than 50 programs have been completed from discovery to manufacturing in as little as 2.5 years. Toxicology: Suzhou GLP facility is the only lab in China with dual certification from OECD & sFDA. US GLP center specializes in medical devices, and gene & cell therapeutic biodistribution studies. All toxicology facilities are AAALAC accredited. Bioanalytical: FDA-inspected laboratory in China has analyzed more than 500,000 clinical samples. Recently opened bioanalytical lab in the US. Pharmaceutical and Biologics GMP Manufacturing: Pharmaceutical CMC services for intermediates & APIs, delivering more than 120 APIs & 160 Clinical Trial batches. GMP manufacturing is available for cell therapy & tissue-based products. More than 1,000 GMP lots have been produced. Combination Products: Unique experience to support companies developing combination products (drug-coated stents, tissue-based products used for wound healing, etc.) requiring expertise and understanding of the regulatory requirements involving multiple regulatory agency approval, (e.g., US FDA CBER/CDRH or CDER /CDRH). ALLIANCES Below are several recent announced collaborations for public release. Other collaborations are ongoing or not publicly announced yet. NEW YORK and SHANGHAI, March 7, 2011: Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility. March 2010: WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training. December 2009: WuXi PharmaTech Selects Labcyte POD™ 810 Platform for High-Throughput Screening. In-Vitro ADME Collaboration with Pfizer through 2011. Integrated Pharmaceutical Research and Dev. collaboration with Johnson & Johnson Pharmaceutical R&D (J&JPRD) for discovery chemistry, discovery biology, chemical and analytical development. Profiles – 105